About US
Contact us
-
Zetia generics launch sets Merck up for $1.4B hit to 2017 cholesterol salesMerck & Co.'s big-selling cholesterol-fighter Zetia is at the end of its exclusive road. The $2.5 billion sellernow faces its first generic competitor, which threatens not only its own revenue, bu2016/12/12
-
GSK promotes Willemsen as China head, will 'put more energy' into growth prospectsCEO Andrew Witty recently indicatedthat GlaxoSmithKline’s China business has "fundamentally"returned to growth years after being embroiled in a bribery scandal. Now, the company has tapped a new China2016/12/12
-
Analysts to Wall Street: Don't celebrate yet. The drug-pricing brouhaha is far from overWhen presidential candidate Hillary Clinton blasted Martin Shkreli on Twitter for hiking the price of an old drug called Daraprim by 5,000% in September 2015, biotech stocks plummeted. Clinton tweeted2016/12/9
-
What puts a new drug launch in line for victory? Ask Gilead, Biogen and J&JDrugmakers spend billions on R&D every year, hoping to createa drug that can throw a commercial punch. It’s never perfectly clear which projects will reach the market, much less deliver big sales,2016/12/9
-
Once-spurned cancer drugs win NICE's favor with—no surprise—'sensible pricing'England’s cost-effectiveness watchdogs are a tough audience, and they've often angered cancer drugmakers when meds were turned away. Recently, however, a steady stream of oncology meds have made it th2016/12/8
-
Supreme Court urged to weigh in on six-month biosimilar delaysNovartis’ Sandoz unit has been marketing Zarxio, its biosimilar version of Amgen’s blockbuster drug Neupogen, for more than a year, but the drug is still tangled in a patent fight that boils down to o2016/12/8
-
Here's an FDA overhaul: Trump considers Thiel VC partner as commissioner, Bloomberg reportsIf President-elect Donald Trump is to “reform” the FDA as he's promised, he might start with an outsider pick to lead the agency. According to Bloomberg’s sources, the incoming administration is consi2016/12/7
-
U.K. watchdog smacks Pfizer with record fine, citing a 2,600% price hikeThe U.K. government slapped Pfizer with a recordfine for an epilepsy drug licensing deal that triggereda 2,600% price increase. The Competition and Markets AuthoritysaysPfizer dodged price controls b2016/12/7
-
Lilly's Jardiance snags FDA approval for reducing CV risk in Type 2 diabetesEli Lilly got a big boost for its diabetes drug franchise on Friday when the FDA approved its SGLT2 diabetes drug Jardiance to reduce the risk of cardiovascular death in adult patients with Type 2 dia2016/12/6
-
UPDATED: New cancer drug benefit study sure to add to debate over drug pricesDrugmakers are already facing growing backlash to the perceived high prices of drugs, but a new study about the real benefits of cancer drugs is sure to add fuel to the fire. It says that follow-up st2016/12/6